Zypitamag Alternatives Compared
| Zypitamag (pitavastatin) | Evolocumab | Leqvio (inclisiran) |
|
|---|
| Zypitamag (pitavastatin) | Evolocumab | Leqvio (inclisiran) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Dyslipidemia, High Cholesterol. Zypitamag may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol. Evolocumab may also be used for purposes not listed... View more |
Prescription only
Prescribed for High Cholesterol - Familial Heterozygous, High Cholesterol. Leqvio may also be used for purposes not listed in this medication guide. |
Related suggestions High Cholesterol
|
|||||||
| More about Zypitamag (pitavastatin) | More about Evolocumab | More about Leqvio (inclisiran) | ||||||||
| Ratings & Reviews | ||||||||||
|
Zypitamag has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Evolocumab has an average rating of 5.4 out of 10 from a total of 676 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 44% reported a negative effect. |
Leqvio has an average rating of 7.2 out of 10 from a total of 72 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 6% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Leqvio prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
||||||||
| Brand Names | ||||||||||
| Other pitavastatin brands include: Livalo | Repatha |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
12 hours |
408 hours |
9 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 166 drugs are known to interact with Zypitamag:
|
A total of 2 drugs are known to interact with Evolocumab:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||
| First Approval Date | ||||||||||
|
July 14, 2017 |
N/A |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.